Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Pharmacogenomics and Laboratory Medicine
135
Hamburg, M.A., and Collins, F.S. (2010). The path to personalized medicine. The New
England Journal of Medicine 363, 301–304.
Hampel, H. (2009). Genetic testing for hereditary colorectal cancer. Surgical Oncology
Clinics of North America 18, 687–703.
Hegde, M.R., and Roa, B.B. (2009). Genetic testing for hereditary nonpolyposis colorectal
cancer (HNPCC). Current Protocols in Human Genetics 61, 10.12.1–10.12.28.
Hein, D.W., Grant, D.M., and Sim, E. (2000). Update on consensus arylamine
N-acetyltransferase gene nomenclature. Pharmacogenetics 10, 291–292.
Heisterkamp, N., and Groffen, J. (1991). Molecular insights into the Philadelphia translocation.
Hematologic Pathology 5, 1–10.
Hicks, J.K., Swen, J.J., Thorn, C.F., Sangkuhl, K., Kharasch, E.D., Ellingrod, V.L., Skaar, T.C.,
et al. (2013). Clinical Pharmacogenetics Implementation Consortium guideline for
CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clinical
Pharmacology and Therapeutics 93, 402–408.
Higashi, M.K., Veenstra, D.L., Kondo, L.M., Wittkowsky, A.K., Srinouanprachanh, S.L.,
Farin, F.M., and Rettie, A.E. (2002). Association between CYP2C9 genetic variants
and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690–1698.
Honchel, R., Aksoy, I.A., Szumlanski, C., Wood, T.C., Otterness, D.M., Wieben, E.D., and
Weinshilboum, R.M. (1993). Human thiopurine methyltransferase: Molecular cloning and
expression of T84 colon carcinoma cell cDNA. Molecular Pharmacology 43, 878–887.
Hwang, S.J., Lozano, G., Amos, C.I., and Strong, L.C. (2003). Germline p53 mutations in a
cohort with childhood sarcoma: Sex differences in cancer risk. American Journal of
Human Genetics 72, 975–983.
Imai, Y., Nakane, M., Kage, K., Tsukahara, S., Ishikawa, E., Tsuruo, T., Miki, Y., and
Sugimoto, Y. (2002). C421A polymorphism in the human breast cancer resistance protein
gene is associated with low expression of Q141K protein and low-level drug resistance.
Molecular Cancer Therapeutics 1, 611–616.
Inamura, K., Takeuchi, K., Togashi, Y., Hatano, S., Ninomiya, H., Motoi, N., Mun, M.Y.,
et al. (2009). EML4-ALK lung cancers are characterized by rare other mutations,
a TTF-1 cell lineage, an acinar histology, and young onset. Modern Pathology 22,
508–515.
Inamura, K., Takeuchi, K., Togashi, Y., Nomura, K., Ninomiya, H., Okui, M., Satoh, Y., et al.
(2008). EML4-ALK fusion is linked to histological characteristics in a subset of lung
cancers. Journal of Thoracic Oncology 3, 13–17.
Ingelman-Sundberg, M. (2011). The human cytochrome P450 (CYP) allele nomenclature
database. CYP2C19 allele nomenclature. http://www.cypalleleskise/cyp2c19htm
Ingelman-Sundberg, M., Oscarson, M., and McLellan, R.A. (1999). Polymorphic human
cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends
in Pharmacological Sciences 20, 342–349.
Ingelman-Sundberg, M., Sim, S.C., Gomez, A., and Rodriguez-Antona, C. (2007). Influence
of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic
and clinical aspects. Pharmacology & Therapeutics 116, 496–526.
Innocenti, F., Vokes, E.E., and Ratain, M.J. (2006). Irinogenetics: What is the right star?
Journal of Clinical Oncology 24, 2221–2224.
Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B.,
and Yamamoto, T. (1997). Molecular characterization of ALK, a receptor tyrosine
kinase expressed specifically in the nervous system. Oncogene 14, 439–449.
Janavicius, R. (2010). Founder BRCA1/2 mutations in the Europe: Implications for hereditary
breast-ovarian cancer prevention and control. The EPMA Journal 1, 397–412.
Kalow, W., Tang, B.K., and Endrenyi, L. (1998). Hypothesis: Comparisons of inter- and intraindividual
variations can substitute for twin studies in drug research. Pharmacogenetics
8, 283–289.